Dupixent (dupilumab) could serve as a promising treatment option for patients with atopic dermatitis (AD) who also have alopecia areata (AA) and/or vitiligo , as these conditions share immune pathways targeted by the drug, according to an analysis recently published in the Journal of the American Academy of Dermatology case reports.

Dupixent is a targeted biologic therapy that blocks the inflammatory signals of interleukin (IL)-4 and IL-13, key drivers of immune overactivity in several chronic diseases. The drug is FDA-approved for many conditions, including moderate-to-severe atopic dermatitis, certain types of asthma, chronic rhinosinusitis with nasal polyps and eosinophilic esophagitis.

According to researchers, there is growing interest in the drug’s potential use for other immun

See Full Page